Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Anti-infective agents

US approves new antibiotic for life-threatening infections

x-ray of intestinal abdominal 14


Cubist Pharmaceutical’s combination drug Zerbaxa has been approved in the United States to treat complicated urinary tract and intra-abdominal infections (pictured), making it the the fourth new antibiotic to be approved by the regulator in 2014

The US Food and Drug Administration (FDA) has approved the use of a new antibiotic, ceftolozane plus tazobactam (Zerbaxa), for the treatment of adults with complicated intra-abdominal infections and complicated urinary tract infections. 

The product approval was fast-tracked after it was given Qualified Infectious Disease Product status by the FDA in recognition of its potential to treat serious or life-threatening infections and as part of the agency’s drive to increase antibacterial and antibiotic product options for patients. It is the fourth new antibacterial to be given the go-ahead by the FDA this year. 

Zerbaxa combines ceftolozane, a cephalosporin antibacterial drug, and tazobactam, a beta-lactamase inhibitor. 

Drug manufacturer Cubist Pharmaceuticals described the approval of ceftolozane/tazobactam as an important day for patients. 

“We are very pleased to arm physicians with Zerbaxa in the battle against Gram-negative bacteria, where few treatment options exist. The approval…demonstrates the agency’s commitment to make available new antibiotics that address this serious public health threat,” said Robert J Perez, the company’s president and chief operating officer. 

Ceftolozane/tazobactam is currently unavailable in the UK and the European Union (EU). 

The EU regulator, the European Medicines Agency (EMA), confirmed on 22 December 2014 that an application has been submitted for ceftolozane/tazobactam and is currently being assessed by its Committee for Medicinal Products for Human Use (CHMP).

The EMA said its scientific opinion will be made available at a future date.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067484

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • x-ray of intestinal abdominal 14

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.